Global Drive-through COVID-19 Testing Market

Drive-through COVID-19 Testing Comprehensive Study by Type (Molecular Test, Antigen Test, Antibody Test), Application (Hospital, Residential area, Workplace, Others), Sample Type (Blood, Nasal swabs, Oropharyngeal swab, Others), Age Group (Pediatric, Adults, Geriatric) Players and Region - Global Market Outlook to 2028

Drive-through COVID-19 Testing Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Industry Background:
A COVID-19 drive-through test is the most efficient method for diagnosing an active coronavirus infection while minimizing the further spread of the contagious disease. In a drive-through COVID-19 test, people are quarantined in their car, isolated from others, and the testing procedure is conducted in a well-ventilated environment The findings from the University of Georgia study conclude that you are more likely to infect others or become infected with COVID-19 in an indoor space such as a hospital or clinic while waiting for hours to get tested.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)
Key Companies ProfiledBioMednomics (United States), Getein Biotech (China), Biomaxima (Poland), Sensing Self Ltd (Singapore), Genetix Biotech Asia Pvt. Ltd. (India), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), RayBiotech (United States), Alercell (United States) and Atila Biosystem (United States)


This growth is primarily driven by Launch of Innovative product to covid 19 test..

Globally, a noticeable market trend is evident Major Players, such as BioMednomics (United States), Getein Biotech (China), Biomaxima (Poland), Sensing Self Ltd (Singapore), Genetix Biotech Asia Pvt. Ltd. (India), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), RayBiotech (United States), Alercell (United States) and Atila Biosystem (United States), etc have either set up their manufacturing facilities or are planning to start new provision in the dominated region in the upcoming years. Drive through Covid-19 Testing market Competitive Landscape Provides Details by Competitor. Details Included Are Company Overview, Company Financials, Revenue Generated, Market Potential, Investment in Research and Development, New Market Initiatives, Global Presence, Production Sites and Facilities, Production Capacities, Company Strengths And Weaknesses, Product Launch, Product Width And Breadth, Application Dominance. The companies are coming up with partnerships or agreements along with planning strategic activities such as partnerships, product launches, mergers, and acquisitions which will help them to sustain in the market and maintain their competitive edge.

Key Developments in the Market:

In March 2020, Bio Medomics Announce the Launch of a Rapid Serology Test to Detect Exposure to COVID-19. the release of a new point-of-care test that can detect antibodies in blood to confirm current or past exposure to COVID-19 in as little as 15 minutes. BioMedomics is a point-of-care diagnostics company that aims to provide novel, rapid point-of-care tests to aid in the diagnosis of critical diseases.

Market Growth Drivers:
Launch of Innovative product to covid 19 test.

Challenges:
Uncomfortable for some people

Restraints:
Limitation of testing kits.

AMA Research follows a focused and realistic research framework that provides the ability to study the crucial market dynamics in several regions across the world. Moreover, an in-depth assessment is mostly conducted by our analysts on geographical regions to provide clients and businesses the opportunity to dominate in niche markets and expand in emerging markets across the globe. This market research study also showcases the spontaneously changing Players landscape impacting the growth of the market. Furthermore, our market researchers extensively analyze the products and services offered by multiple players competing to increase their market share and presence.

Customization in the Report
AMA Research features not only specific market forecasts but also includes significant value-added commentary on:
- Market Trends
- Technological Trends and Innovations
- Market Maturity Indicators
- Growth Drivers and Constraints in Drive-through COVID-19 Testing Market
- Analysis about New Entrants in Drive-through COVID-19 Testing Market & Entry/Exit Barriers
- To Seize Powerful Market Opportunities
- Identify Key Business Segments, Market Proposition & Gap Analysis
- An Unbiased Perspective towards Market Performance & Indicators

Against this Challenging Backdrop, Drive-through COVID-19 Testing Study Sheds Light on
— The Drive-through COVID-19 Testing Market status quo and key characteristics. To end this, Analysts at AMA organize and took surveys of the Drive-through COVID-19 Testing industry Players. The resultant snapshot serves as a basis for understanding why and how the industry can be expected to change.
— Where Drive-through COVID-19 Testing industry is heading and what are the top priorities. Insights are drawn from financial analysis, surveys, and interviews with key executives and industry experts.
— How every company in this diverse set of Players can best navigate the emerging competition landscape and follow a strategy that helps them position to hold the value they currently claim or capture the new addressable opportunity.

Report Objectives / Segmentation Covered

By Type
  • Molecular Test
  • Antigen Test
  • Antibody Test
By Application
  • Hospital
  • Residential area
  • Workplace
  • Others
By Sample Type
  • Blood
  • Nasal swabs
  • Oropharyngeal swab
  • Others

By Age Group
  • Pediatric
  • Adults
  • Geriatric

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Launch of Innovative product to covid 19 test.
    • 3.3. Market Challenges
      • 3.3.1. Uncomfortable for some people
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Drive-through COVID-19 Testing, by Type, Application, Sample Type , Age Group and Region (value) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Drive-through COVID-19 Testing (Value)
      • 5.2.1. Global Drive-through COVID-19 Testing by: Type (Value)
        • 5.2.1.1. Molecular Test
        • 5.2.1.2. Antigen Test
        • 5.2.1.3. Antibody Test
      • 5.2.2. Global Drive-through COVID-19 Testing by: Application (Value)
        • 5.2.2.1. Hospital
        • 5.2.2.2. Residential area
        • 5.2.2.3. Workplace
        • 5.2.2.4. Others
      • 5.2.3. Global Drive-through COVID-19 Testing Region
        • 5.2.3.1. South America
          • 5.2.3.1.1. Brazil
          • 5.2.3.1.2. Argentina
          • 5.2.3.1.3. Rest of South America
        • 5.2.3.2. Asia Pacific
          • 5.2.3.2.1. China
          • 5.2.3.2.2. Japan
          • 5.2.3.2.3. India
          • 5.2.3.2.4. South Korea
          • 5.2.3.2.5. Taiwan
          • 5.2.3.2.6. Australia
          • 5.2.3.2.7. Rest of Asia-Pacific
        • 5.2.3.3. Europe
          • 5.2.3.3.1. Germany
          • 5.2.3.3.2. France
          • 5.2.3.3.3. Italy
          • 5.2.3.3.4. United Kingdom
          • 5.2.3.3.5. Netherlands
          • 5.2.3.3.6. Rest of Europe
        • 5.2.3.4. MEA
          • 5.2.3.4.1. Middle East
          • 5.2.3.4.2. Africa
        • 5.2.3.5. North America
          • 5.2.3.5.1. United States
          • 5.2.3.5.2. Canada
          • 5.2.3.5.3. Mexico
  • 6. Drive-through COVID-19 Testing: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. BioMednomics (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Getein Biotech (China)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Biomaxima (Poland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Sensing Self Ltd (Singapore)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Genetix Biotech Asia Pvt. Ltd. (India)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Thermo Fisher Scientific (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Abbott Laboratories (United States)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. RayBiotech (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Alercell (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Atila Biosystem (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Drive-through COVID-19 Testing Sale, by Type, Application, Sample Type , Age Group and Region (value) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Drive-through COVID-19 Testing (Value)
      • 7.2.1. Global Drive-through COVID-19 Testing by: Type (Value)
        • 7.2.1.1. Molecular Test
        • 7.2.1.2. Antigen Test
        • 7.2.1.3. Antibody Test
      • 7.2.2. Global Drive-through COVID-19 Testing by: Application (Value)
        • 7.2.2.1. Hospital
        • 7.2.2.2. Residential area
        • 7.2.2.3. Workplace
        • 7.2.2.4. Others
      • 7.2.3. Global Drive-through COVID-19 Testing Region
        • 7.2.3.1. South America
          • 7.2.3.1.1. Brazil
          • 7.2.3.1.2. Argentina
          • 7.2.3.1.3. Rest of South America
        • 7.2.3.2. Asia Pacific
          • 7.2.3.2.1. China
          • 7.2.3.2.2. Japan
          • 7.2.3.2.3. India
          • 7.2.3.2.4. South Korea
          • 7.2.3.2.5. Taiwan
          • 7.2.3.2.6. Australia
          • 7.2.3.2.7. Rest of Asia-Pacific
        • 7.2.3.3. Europe
          • 7.2.3.3.1. Germany
          • 7.2.3.3.2. France
          • 7.2.3.3.3. Italy
          • 7.2.3.3.4. United Kingdom
          • 7.2.3.3.5. Netherlands
          • 7.2.3.3.6. Rest of Europe
        • 7.2.3.4. MEA
          • 7.2.3.4.1. Middle East
          • 7.2.3.4.2. Africa
        • 7.2.3.5. North America
          • 7.2.3.5.1. United States
          • 7.2.3.5.2. Canada
          • 7.2.3.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Drive-through COVID-19 Testing: by Type(USD Million)
  • Table 2. Drive-through COVID-19 Testing Molecular Test , by Region USD Million (2017-2022)
  • Table 3. Drive-through COVID-19 Testing Antigen Test , by Region USD Million (2017-2022)
  • Table 4. Drive-through COVID-19 Testing Antibody Test , by Region USD Million (2017-2022)
  • Table 5. Drive-through COVID-19 Testing: by Application(USD Million)
  • Table 6. Drive-through COVID-19 Testing Hospital , by Region USD Million (2017-2022)
  • Table 7. Drive-through COVID-19 Testing Residential area , by Region USD Million (2017-2022)
  • Table 8. Drive-through COVID-19 Testing Workplace , by Region USD Million (2017-2022)
  • Table 9. Drive-through COVID-19 Testing Others , by Region USD Million (2017-2022)
  • Table 10. South America Drive-through COVID-19 Testing, by Country USD Million (2017-2022)
  • Table 11. South America Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 12. South America Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 13. South America Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 14. South America Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 15. Brazil Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 16. Brazil Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 17. Brazil Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 18. Brazil Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 19. Argentina Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 20. Argentina Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 21. Argentina Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 22. Argentina Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 23. Rest of South America Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 24. Rest of South America Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 25. Rest of South America Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 26. Rest of South America Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 27. Asia Pacific Drive-through COVID-19 Testing, by Country USD Million (2017-2022)
  • Table 28. Asia Pacific Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 29. Asia Pacific Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 30. Asia Pacific Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 31. Asia Pacific Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 32. China Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 33. China Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 34. China Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 35. China Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 36. Japan Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 37. Japan Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 38. Japan Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 39. Japan Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 40. India Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 41. India Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 42. India Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 43. India Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 44. South Korea Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 45. South Korea Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 46. South Korea Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 47. South Korea Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 48. Taiwan Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 49. Taiwan Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 50. Taiwan Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 51. Taiwan Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 52. Australia Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 53. Australia Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 54. Australia Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 55. Australia Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 56. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 57. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 58. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 59. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 60. Europe Drive-through COVID-19 Testing, by Country USD Million (2017-2022)
  • Table 61. Europe Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 62. Europe Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 63. Europe Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 64. Europe Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 65. Germany Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 66. Germany Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 67. Germany Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 68. Germany Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 69. France Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 70. France Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 71. France Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 72. France Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 73. Italy Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 74. Italy Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 75. Italy Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 76. Italy Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 77. United Kingdom Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 78. United Kingdom Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 79. United Kingdom Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 80. United Kingdom Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 81. Netherlands Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 82. Netherlands Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 83. Netherlands Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 84. Netherlands Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 85. Rest of Europe Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 86. Rest of Europe Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 87. Rest of Europe Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 88. Rest of Europe Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 89. MEA Drive-through COVID-19 Testing, by Country USD Million (2017-2022)
  • Table 90. MEA Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 91. MEA Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 92. MEA Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 93. MEA Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 94. Middle East Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 95. Middle East Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 96. Middle East Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 97. Middle East Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 98. Africa Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 99. Africa Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 100. Africa Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 101. Africa Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 102. North America Drive-through COVID-19 Testing, by Country USD Million (2017-2022)
  • Table 103. North America Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 104. North America Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 105. North America Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 106. North America Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 107. United States Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 108. United States Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 109. United States Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 110. United States Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 111. Canada Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 112. Canada Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 113. Canada Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 114. Canada Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 115. Mexico Drive-through COVID-19 Testing, by Type USD Million (2017-2022)
  • Table 116. Mexico Drive-through COVID-19 Testing, by Application USD Million (2017-2022)
  • Table 117. Mexico Drive-through COVID-19 Testing, by Sample Type USD Million (2017-2022)
  • Table 118. Mexico Drive-through COVID-19 Testing, by Age Group USD Million (2017-2022)
  • Table 119. Company Basic Information, Sales Area and Its Competitors
  • Table 120. Company Basic Information, Sales Area and Its Competitors
  • Table 121. Company Basic Information, Sales Area and Its Competitors
  • Table 122. Company Basic Information, Sales Area and Its Competitors
  • Table 123. Company Basic Information, Sales Area and Its Competitors
  • Table 124. Company Basic Information, Sales Area and Its Competitors
  • Table 125. Company Basic Information, Sales Area and Its Competitors
  • Table 126. Company Basic Information, Sales Area and Its Competitors
  • Table 127. Company Basic Information, Sales Area and Its Competitors
  • Table 128. Company Basic Information, Sales Area and Its Competitors
  • Table 129. Drive-through COVID-19 Testing: by Type(USD Million)
  • Table 130. Drive-through COVID-19 Testing Molecular Test , by Region USD Million (2023-2028)
  • Table 131. Drive-through COVID-19 Testing Antigen Test , by Region USD Million (2023-2028)
  • Table 132. Drive-through COVID-19 Testing Antibody Test , by Region USD Million (2023-2028)
  • Table 133. Drive-through COVID-19 Testing: by Application(USD Million)
  • Table 134. Drive-through COVID-19 Testing Hospital , by Region USD Million (2023-2028)
  • Table 135. Drive-through COVID-19 Testing Residential area , by Region USD Million (2023-2028)
  • Table 136. Drive-through COVID-19 Testing Workplace , by Region USD Million (2023-2028)
  • Table 137. Drive-through COVID-19 Testing Others , by Region USD Million (2023-2028)
  • Table 138. South America Drive-through COVID-19 Testing, by Country USD Million (2023-2028)
  • Table 139. South America Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 140. South America Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 141. South America Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 142. South America Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 143. Brazil Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 144. Brazil Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 145. Brazil Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 146. Brazil Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 147. Argentina Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 148. Argentina Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 149. Argentina Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 150. Argentina Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 151. Rest of South America Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 152. Rest of South America Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 153. Rest of South America Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 154. Rest of South America Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 155. Asia Pacific Drive-through COVID-19 Testing, by Country USD Million (2023-2028)
  • Table 156. Asia Pacific Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 157. Asia Pacific Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 158. Asia Pacific Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 159. Asia Pacific Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 160. China Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 161. China Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 162. China Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 163. China Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 164. Japan Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 165. Japan Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 166. Japan Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 167. Japan Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 168. India Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 169. India Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 170. India Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 171. India Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 172. South Korea Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 173. South Korea Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 174. South Korea Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 175. South Korea Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 176. Taiwan Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 177. Taiwan Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 178. Taiwan Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 179. Taiwan Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 180. Australia Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 181. Australia Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 182. Australia Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 183. Australia Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 184. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 185. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 186. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 187. Rest of Asia-Pacific Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 188. Europe Drive-through COVID-19 Testing, by Country USD Million (2023-2028)
  • Table 189. Europe Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 190. Europe Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 191. Europe Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 192. Europe Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 193. Germany Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 194. Germany Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 195. Germany Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 196. Germany Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 197. France Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 198. France Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 199. France Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 200. France Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 201. Italy Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 202. Italy Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 203. Italy Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 204. Italy Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 205. United Kingdom Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 206. United Kingdom Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 207. United Kingdom Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 208. United Kingdom Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 209. Netherlands Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 210. Netherlands Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 211. Netherlands Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 212. Netherlands Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 213. Rest of Europe Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 214. Rest of Europe Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 215. Rest of Europe Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 216. Rest of Europe Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 217. MEA Drive-through COVID-19 Testing, by Country USD Million (2023-2028)
  • Table 218. MEA Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 219. MEA Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 220. MEA Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 221. MEA Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 222. Middle East Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 223. Middle East Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 224. Middle East Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 225. Middle East Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 226. Africa Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 227. Africa Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 228. Africa Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 229. Africa Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 230. North America Drive-through COVID-19 Testing, by Country USD Million (2023-2028)
  • Table 231. North America Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 232. North America Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 233. North America Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 234. North America Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 235. United States Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 236. United States Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 237. United States Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 238. United States Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 239. Canada Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 240. Canada Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 241. Canada Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 242. Canada Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 243. Mexico Drive-through COVID-19 Testing, by Type USD Million (2023-2028)
  • Table 244. Mexico Drive-through COVID-19 Testing, by Application USD Million (2023-2028)
  • Table 245. Mexico Drive-through COVID-19 Testing, by Sample Type USD Million (2023-2028)
  • Table 246. Mexico Drive-through COVID-19 Testing, by Age Group USD Million (2023-2028)
  • Table 247. Research Programs/Design for This Report
  • Table 248. Key Data Information from Secondary Sources
  • Table 249. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Drive-through COVID-19 Testing: by Type USD Million (2017-2022)
  • Figure 5. Global Drive-through COVID-19 Testing: by Application USD Million (2017-2022)
  • Figure 6. South America Drive-through COVID-19 Testing Share (%), by Country
  • Figure 7. Asia Pacific Drive-through COVID-19 Testing Share (%), by Country
  • Figure 8. Europe Drive-through COVID-19 Testing Share (%), by Country
  • Figure 9. MEA Drive-through COVID-19 Testing Share (%), by Country
  • Figure 10. North America Drive-through COVID-19 Testing Share (%), by Country
  • Figure 11. Global Drive-through COVID-19 Testing share by Players 2022 (%)
  • Figure 12. Global Drive-through COVID-19 Testing share by Players (Top 3) 2022(%)
  • Figure 13. Global Drive-through COVID-19 Testing share by Players (Top 5) 2022(%)
  • Figure 14. BCG Matrix for key Companies
  • Figure 15. BioMednomics (United States) Revenue, Net Income and Gross profit
  • Figure 16. BioMednomics (United States) Revenue: by Geography 2022
  • Figure 17. Getein Biotech (China) Revenue, Net Income and Gross profit
  • Figure 18. Getein Biotech (China) Revenue: by Geography 2022
  • Figure 19. Biomaxima (Poland) Revenue, Net Income and Gross profit
  • Figure 20. Biomaxima (Poland) Revenue: by Geography 2022
  • Figure 21. Sensing Self Ltd (Singapore) Revenue, Net Income and Gross profit
  • Figure 22. Sensing Self Ltd (Singapore) Revenue: by Geography 2022
  • Figure 23. Genetix Biotech Asia Pvt. Ltd. (India) Revenue, Net Income and Gross profit
  • Figure 24. Genetix Biotech Asia Pvt. Ltd. (India) Revenue: by Geography 2022
  • Figure 25. Thermo Fisher Scientific (United States) Revenue, Net Income and Gross profit
  • Figure 26. Thermo Fisher Scientific (United States) Revenue: by Geography 2022
  • Figure 27. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 28. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 29. RayBiotech (United States) Revenue, Net Income and Gross profit
  • Figure 30. RayBiotech (United States) Revenue: by Geography 2022
  • Figure 31. Alercell (United States) Revenue, Net Income and Gross profit
  • Figure 32. Alercell (United States) Revenue: by Geography 2022
  • Figure 33. Atila Biosystem (United States) Revenue, Net Income and Gross profit
  • Figure 34. Atila Biosystem (United States) Revenue: by Geography 2022
  • Figure 35. Global Drive-through COVID-19 Testing: by Type USD Million (2023-2028)
  • Figure 36. Global Drive-through COVID-19 Testing: by Application USD Million (2023-2028)
  • Figure 37. South America Drive-through COVID-19 Testing Share (%), by Country
  • Figure 38. Asia Pacific Drive-through COVID-19 Testing Share (%), by Country
  • Figure 39. Europe Drive-through COVID-19 Testing Share (%), by Country
  • Figure 40. MEA Drive-through COVID-19 Testing Share (%), by Country
  • Figure 41. North America Drive-through COVID-19 Testing Share (%), by Country
List of companies from research coverage that are profiled in the study
  • BioMednomics (United States)
  • Getein Biotech (China)
  • Biomaxima (Poland)
  • Sensing Self Ltd (Singapore)
  • Genetix Biotech Asia Pvt. Ltd. (India)
  • Thermo Fisher Scientific (United States)
  • Abbott Laboratories (United States)
  • RayBiotech (United States)
  • Alercell (United States)
  • Atila Biosystem (United States)
Select User Access Type

Key Highlights of Report


Jun 2023 215 Pages 77 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Drive-through COVID-19 Testing Market Quantitative research analysis
Global Drive-through COVID-19 Testing Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Drive-through COVID-19 Testing market are BioMednomics (United States), Getein Biotech (China), Biomaxima (Poland), Sensing Self Ltd (Singapore), Genetix Biotech Asia Pvt. Ltd. (India), Thermo Fisher Scientific (United States), Abbott Laboratories (United States), RayBiotech (United States), Alercell (United States) and Atila Biosystem (United States), to name a few.
is dominating the Drive-through COVID-19 Testing Market.
"Uncomfortable for some people" is seen as one of the major challenges by many Industry Players of Drive-through COVID-19 Testing Market
The Drive-through COVID-19 Testing market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get complete companies available in our research coverage.
The Drive-through COVID-19 Testing market is expected to see a steady growth rate during projected year 2022 to 2028.

Know More About Global Drive-through COVID-19 Testing Market Report?

Have a Query? Click Here

Other Related Reports

Next Generation Probiotics Comprehensive Study by Application (Autoimmune Diseases, Glucose Management, Inflammatory Bowel Disease, Others), Category (Akkermansia Muciniphila, Faecalibacterium Prausn...
$ 3800
Medical Manuka Honey Comprehensive Study by Application (Healthcare, Skin Care Industry, Others), Distribution Channel (Online, Offline), Category Type (K-Factor, K-Factor 12, K-Factor 16, K-Factor 2...
$ 3800
Digital Payment in Healthcare Comprehensive Study by Type (On-Premise, Cloud), By Enterprise size (Small size, Medium size, Large size), By Component (Solution, Service, Intelligence), Payment Mode...
$ 3800
Cell Therapy Market Comprehensive Study by Application (Musculoskeletal, Malignancies, Cardiovascular, Dermatology and Wounds, Other), Type (Autologous, Allogeneic), End User (Hospitals, Homecare, S...
$ 3800
Big Data in the Healthcare & Pharmaceutical Industry Comprehensive Study by Application (Financial Analytics, Clinical Data Analytics, Operational Analytics, Population Health Analytics), Deployment ...
$ 3800
Acupuncture- Comprehensive Study by Type (Needle Acupuncture, Moxibustion Acupuncture, Cupping, Auricular, Others), End-User (Hospitals, Speciality clinics, Wellness Centre, Others), Needle Type (Non...
$ 3800